Back to News
Market Impact: 0.25
Rona Therapeutics Licenses Obesity Drug Candidate To Roche In Deal Worth Up To $1.16 Billion
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
Rona Therapeutics entered a global licensing agreement with Roche for an investigational RNAi therapy targeting ALK7, a genetically validated target for obesity and metabolic diseases. The article provides no financial terms, development milestones, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
ROP0.50
More News
- South Korean carmaker Hyundai plans 'strategic' investment of $15.5 billion in India by 2032
- Applied Materials’ $5 billion AI lab aims to cut chip development time in half—and restore Silicon Valley’s edge
- Meta’s Muse models reach the AI frontier—and kill any hopes to ‘pace’ it
- Mainspring, AEP Strike Deal to Bring Power Online Faster
- Why this little known Chinese chipmaker has caused a global stock rout
- Applied Materials CEO on Doubling Revenue Thanks To AI